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Policy Points:
 The patient-reported outcome (PRO) is a standardized method for
measuring patients’ views of their health status. Our international
study showed that experts in clinical practice and performance mea-
surement supported the integrated collection of PRO data for use in
both clinical care and performance measurement.
 The measurement of PROs to support patient-provider decisions and
the use of PRO performancemeasures to evaluate health care providers
have developed both separately and in parallel.
 The use of PROs would benefit from a shared vision by health care
providers, purchasers of care, and patients regarding the aims and
purposes of the various applications; and the establishment of trust
among stakeholders concerning the prudent use of PRO performance
measures.
Context: Patient-reported outcomes (PROs) can play an important role in
patient-centered health care by focusing on the patient’s health goals guiding
therapeutic decisions. When aggregated, PROs also can be used for other
purposes, including comparative effectiveness research, practice improvement,
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assessment of the performance of clinicians and organizations, and as a metric
for value-based payments. The feasibility of integrating the use of PROs for
these various purposes on a wide scale has not yet been demonstrated. Our study
was conducted to inform policymakers of prudent next steps for implementing
PROs in clinical practice and performance measurement programs in order to
maximize their impact on the quality of health care.
Methods:Weconducted a qualitative study, interviewing 58 experts and leaders
from 37 organizations (response rate: 88%) in the United States, England,
and the Netherlands. Respondents included clinical practitioners (n = 30),
measure developers (n= 11), and leaders of performancemeasurement programs
(n = 17). We used a qualitative content analysis to assess current strategies
for applying PROs in clinical practice and performance measurement and to
identify barriers to and facilitators of further implementation.
Findings: The use of PROs in clinical practice and for performance measure-
ment has developed both separately and in parallel. Experts across the stake-
holder spectrum support the collection of PRO data in an integrated manner
that would enable using the data for these distinct purposes. We identified 2
main concerns about the feasibility for integrated use of PRO data: the complex-
ity of establishing routine data collection and the tension among stakeholders
when using PRO data for different purposes. These contrasting stakeholder
views suggested varying interests among clinicians, measure developers, and
purchasers of care.
Conclusions:Data collection approaches that support the use of PROs in health
care are underdeveloped, need better integration with clinical care, and must be
tailored to the characteristics of the health care system. Enabling the sustainable
use of PROs will require a shared vision of clinical professionals, purchasers,
and patients, with a prudent selection of the steps in implementing PROs that
will maximize their impact on the quality of health care.
Keywords: patient-reported outcomes, health care policy, quality of care, per-
formance measurement.
T he patient-reported outcome (PRO) is a standardizedmethod for measuring patients’ views of their health and health-related quality of life, and the results are expected to play several
roles in advancing patient-centered health care. In clinical practice, clin-
icians can use them to focus on a patient’s individual health goals and
guide diagnostic and treatment decisions. PROs are central to patient-
centered comparative effectiveness research.1,2 Aggregated across
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patients, PRO results can be used to guide efforts for clinical qual-
ity improvement, for public reporting, and for value-based payments.3
PROs also can be used in comparative performance reporting for practice
improvement andmade part of the continuous professional development
and maintenance of certification of licensure.4 Many observers believe
that PRO methodology could be integrated, enabling the same PROs
to be used for multiple purposes.5,6
Typically, PROs are assessed with patient-reported outcome mea-
sures (PROMs), which are collected from questionnaires containing
either multi-item scales or single-item measures. PROMs can be
generic, measuring the health-related quality of life, or disease spe-
cific, assessing components of patients’ functioning related to a spe-
cific disease or condition.7 For example, a well-known generic PROM,
the Short Form Health Survey (SF-36), measures overall quality of
life.8 The Patient Reported Outcome Measurement Information Sys-
tem (PROMIS), developed over the past decade, provides item banks
for measuring patient-reported outcomes for a wide variety of diseases
and conditions, thus forming a hybrid of generic and disease-specific
measures.9
If PRO measures are aggregated across patients, they can be used as
performance measures (PRO-PM) to assess and compare the quality of
care of health care providers or provider organizations.10 In health care,
performance measures are typically used either as a summative mech-
anism for accountability to payers, purchasers, and the public or as a
formative mechanism to assist clinicians and organizations in quality
improvement. For government and regulators, performance information
is used to evaluate the quality of the health care system at an aggregate
level. For purchasers, such as health insurers, insight into the com-
parative quality of health care providers informs selective contracting
and payment incentives. Performance information also helps patients
and consumers in choosing health plans and providers.11 Several clin-
ical quality indicators are now used to support quality improvement
initiatives in hospitals, ambulatory practices, and other settings.12-14
To encourage the use of PROs in clinical practice and perfor-
mance measurement, the National Quality Forum (NQF) in the United
States has described a pathway for developing PRO-based perfor-
mance measures that integrate measurements of both clinical practice
and performance.15 In addition, standards for developing PRO-PMs
have been published, emphasizing the importance of aligning clinical
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practice and performance measurement.16 An important issue in the use
of PROs is the application of case-mix adjustment, stratification, or risk
adjustment to provide fair and meaningful comparisons.7
Although case studies in several countries have illustrated the use
of PRO data in clinical practice settings17,18 and their implementation
at the health system level to measure performance,19-23 these nascent
efforts have not yet demonstrated the feasibility of integrating the use
of PROs on a wide scale. Insights from earlier work on factors that may
facilitate or impede the introduction and implementation of innovations
may help designers of strategies to introduce and implement PROs.24,25
In this article, we summarize experiences in 3 countries with using
PROs in clinical practice and performance measurement. The goal is to
help policymakers choose the best next steps for implementing PROs
in clinical practice and performance measurement programs in order to
maximize their impact on the quality of health care.
Methods
Design and Setting
We hypothesized that integrating the use of PROs for several purposes
is feasible but also will confront formidable implementation barriers. To
identify barriers and facilitators in the implementation of the routine
use of PROs, we conducted structured interviews with selected experts
working in clinical practice, quality measure development, and quality
reporting programs in the United States, England, and the Netherlands.
This international sample allowed us to compare the experiences imple-
menting PROs in different health systems. We chose these 3 nations
because of our knowledge of current policy developments and initiatives
for using PROs in health care organizations at both the national and
local levels.
Philip Van der Wees and Eric Schneider developed a structured inter-
view guide to answer 3 key policy questions:
 What are the current approaches to using PRO measures in clin-
ical practice and performance measurement?
 What are the facilitators of and barriers to the further imple-
mentation of PRO measures in clinical practice and performance
measurement?
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 Is it possible to integrate PRO data collection for use in clinical
practice and performance measurement?
At the start of the interview, we described the use of PROs in clini-
cal practice and performance measurement using the NQF’s definition:
“Any report of the status of a patient’s health condition, health behav-
ior, or experience with healthcare that comes directly from the patient,
without interpretation of the patient’s response by a clinician or anyone
else.”15 In our interviews we focused on patient-reported—that is, self-
reported—health outcomes. We asked the participants to describe their
familiarity with 3 constructs: patient-reported outcomes (PROs), PRO
measures (PROMs), and PRO performance measures (PRO-PMs).
Selection of Key Informants. We identified key informants (experts,
researchers, and leaders) through purposeful sampling from 3 sources:
(1) health care organizations known for implementing the routine use of
PROs in clinical practice, (2) organizations developing PRO measures
and studying their reliability and validity, and (3) quality-reporting
programs as potential users of PRO performance measures. We then
used published descriptions of organizations implementing PROs18 to
identify key informants in the 3 countries through our professional
networks. A similar approach was used to find reporting programs at
the health system level. By email, we invited experts and leaders in 42
organizations stratified by care setting and country. All key informants
received written information about the purpose and procedure of the
interviews and were asked to confirm, by email, their participation. Our
study protocol was approved by the RANDHuman Subjects Protection
Committee.
Interviews. Our interview guide was tailored to the specific context
of health care organizations, measure developers, and reporting pro-
grams. Questions were aimed at identifying the current application of
PRO measures; barriers to and facilitators for the use of PROMs at the
micro-, meso-, and macro-health system levels; and the use of PROMs
for evaluating the quality of care. Van derWees used the interview guide
to conduct semistructured interviews either by telephone or face-to-face
after obtaining oral informed consent based on a standardized consent
script approved by the RAND Human Subjects Protection Committee.
Interviews were audio-recorded only after obtaining the respondent’s
permission.
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Data Analysis. Interviews were transcribed verbatim and entered
into the Atlas.ti software program for qualitative data analysis. We used
qualitative content analysis with a directed approach. Content analysis
is suitable for concept development or model building, and a directed
approach uses themes derived from existing theory or research to guide
the initial coding.26 The framework and the initial corresponding codes
based on relevant aspects of the innovation process and its categories
of factors24 were developed by Van der Wees and Maria Nijhuis-van
der Sanden. Independently, they coded the same 6 transcripts from
key informants in clinical practice, measure developers, and reporting
programs in order to identify any new codes that might have emerged
from the interviews. They then used a log of these new codes to modify
the coding framework. After 2 rounds of discussion, they reached a
consensus on the revised framework, which was reviewed for consistency
by Gert Westert and Eric Schneider. Van der Wees and Nijhuis-van der
Sanden applied the final list of codes to all the interviews.
Based on the coded interview transcripts, we conducted a thematic
analysis to identify current strategies for using PROmeasures in clinical
practice and performance measurement, as well as any barriers to and
facilitators for extending and expanding implementation. The analysis,
based on determinants for implementing innovations,24,27 included (1)
characteristics of the sociopolitical context, such as rules, legislation,
and patient characteristics; (2) characteristics of the organization, such
as information technology (IT) infrastructure; (3) characteristics of the
person adopting the innovations, such as knowledge, skills, and per-
ceived support from colleagues; and (4) characteristics of the innovation
(ie, PROmeasurement), such as complexity, validity, and relative advan-
tage. We synthesized the results across interviews to identify common
and disparate themes by PRO use category and setting.
Findings
Table 1 is an overview of the respondents by their involvement in PROs
and setting. We received responses from 37 organizations (response rate:
88%). The key informants helped find additional experts (n = 21)
in their organizations. As a result, we conducted interviews with 58
respondents: 30 experts in clinical practice, 11 measure developers, and
17 experts in provider performance measurement.
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Table 1. Participating Organizations and Key Informants
Reporting Measure
Programs Developers Providers Total
Country O I O I O I O I
United States 6 10 3 5 7 20 16 35
England 3 3 3 3 4 4 10 10
Netherlands 3 4 3 3 5 6 11 13
Total 12 17 9 11 16 30 37 58
Participants listed in absolute numbers.
O: Organizations; I: Informants.
All the respondents were familiar with the concept of PROs and were
able to describe examples of PROmeasures.Most of the participants were
familiar with the intended use of PROperformancemeasures (comparing
providers or organizations based on patient-reported health outcomes).
The respondents from performancemeasurement programs concentrated
primarily on the development of performance measures. For example,
a reporting program expert stated: “Our survey is not a physician-level
survey. It’s assessing plan performance. It’s a different effort to get it
at the physician level.” This contrasted with the participants in clinical
practice who focused on using PRO measures for clinical care. One
clinical expert reported: “We are not considering the use of PROs for
benchmarking yet. That might be interesting, but we first want to
establish meaningful use of PROs in the clinician-patient interaction.”
Current Approaches in the 3 Countries to Using
PRO Measures
Our analysis identified 3 main approaches to implementing PRO mea-
surement. The first approach is collecting data to guide clinical care
decisions related to screening and diagnosis, treatment planning, and
treatment evaluation. Our interviews revealed that many organizations
were still trying to establish a routine approach to data collection and to
integrate this into the organization’s workflow and the electronic health
record.
Patient-Reported Outcomes, Clinical Practice, Performance Measurement 761
The second approach is collecting data designed and managed by na-
tional, regional, or state organizations rather than the local health care
provider. The central organizations may recruit via mail or electronic
communication (or a health care provider may recruit patients), return-
ing the completed questionnaires to a central survey manager or survey
vendor. The data are not used in the direct clinical care of individual pa-
tients but to calculate performance results for organizations or providers.
We found 3 examples of this route: a national approach in England for
patients who undergo certain elective surgical procedures, the Health
Outcomes Survey (HOS) in the United States for a sample of patients
in Medicare managed care, and the joint collection of PRO and patient
experience data in the Netherlands, based on samples of patients who
had completed their treatment.
The third approach is a hybrid of the others. Data are collected by and
used in the health care organization, as in the first approach, followed
by an aggregation of data at the state or national level to measure
performance. In the state of Minnesota, data are routinely collected by
health care organizations from electronic health records and then are
used to compare the quality of state-level providers. The Group Health
Cooperative in the United States uses a health risk assessment with
outcomes entered by patients into their electronic health record, with
the data used to facilitate clinical care and also for reporting purposes. In
mental health care in theNetherlands, local routine outcomemonitoring
was used to establish a national measurement method. All mental health
care organizations have a mandate to collect and submit PRO data to a
database to create a national benchmark for the quality of care. As one
expert commented: “The primary goal of routine outcome measurement
is to support clinicians in diagnosis and treatment. On top of that, we
said we can aggregate these data to assess the quality of care.”
Integration of Data Collection for Different
Purposes
We found strong support for integrated data collection, regardless of the
approach, especially for using the data for different purposes (see Box 1).
But experts also expressed concerns about the feasibility of integrating
the use of PRO data, based on 2 main issues: (1) the complexity of
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integrated data collection and (2) the tension among the stakeholders in
regard to using the PRO data for different purposes (see Box 2).
Box 1.RepresentativeQuotations FromExperts Supporting Integrated
PRO Data Collection
“With an electronic health record, you could start to incorporate
patient-reported outcomes in your process of care, and then you could
use it on a local level for clinical improvement and clinical tracking
and the need for clinical intensification. You could use it for quality
improvement on a health system level.”
“Groups of clinicians who are responsible for some population could
be the ideal unit for this sequence of local collection of data within
the process of care that’s then usable both for clinical uses and for
quality improvement uses at the aggregated level and then stands as
a legitimate marker for national reporting as well as at a more highly
aggregated level.”
“Aggregate data collection only allows for quality improvement at
a very generic level. I hope that the clinical system will move quickly
to bring bottom-up measures that are safe and acceptable for a single
clinician, a group of clinicians for quality improvement, and then at
aggregate level for national reporting.”
Box 2. Representative Quotations Illustrating Stakeholders’ Contrast-
ing Views of Using PRO Data for Different Purposes
Complexity
“If you were collecting it at the physician level and aggregating it
up to a health plan, it probably would be extremely challenging. It is
probably not impossible but extremely challenging.”
“So I know the National Quality Forum is beginning to look at
performancemeasures around patient reportedmeasures and theymake
a distinction between the measure, the patient reported measure and
the performance measure. But as of now I don’t think they even
have norms, what would be good performance, what would be poor
performance. And that’s where we need to get to. We have a lot of
work.”
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“I think one of the challenges probably would be understanding
all of the hurdles to implementation. So clearly, patient-reported
outcomes for a physician or to use in actually providing care is proba-
bly a little bit easier than getting to the point where you can use it to
assess the quality of a provider type. I think that’s where kind of the
hurdle probably is.”
Tension Among Stakeholders
“It doesn’t automatically translate that those same data [collected in
clinical practice] can also be used in an accountability context because
I think the stakes are much, much higher and the science ought to be
a whole lot stronger in those settings.”
“What makes it complicated is the tension between the bench-
marking organization and the health care organization. You have to
engage clinicians in the added value of benchmarking for quality im-
provement; otherwise they will only submit data to keep the insurance
company happy.”
“That you’re not going to bear down to an individual clinician to
take responsibility for the clinical outcomes in a way that unfairly
holds them responsible for things, either that happened outside of
their control or happened too far temporally outside of their control
or happened just because some patients, through bad luck, are sicker
than others.”
Complexity. Experts emphasized that integrated data collection is
important to maintain the long-term involvement and sustainability of
clinicians. They noted that integrated data collection strengthens the
patient-clinician interaction and encourages use of the data by clinicians
and patients. But the complex steps required to integrate the data for the
use of PROs in both clinical practice and performancemeasurement were
perceived as challenging. Reliable and valid data to support performance
measures require integrated routine electronic data collection in clinical
practice. As one expert summarized the project: “So this is hard, it’s
really hard to get this up and running. To get it electronically and to
get it into the record is tough. There’s going to be some tipping point
that occurs at some point in time where everything becomes electronic.
Once that happens, I think we’ll make rapid progress.”
Differences Among Stakeholders’ Views. Interests in PRO data varied
among clinicians, measure developers, and purchasers of care. Experts
reported that clinicians fear that administrators will misuse the data
when creating performance measures. In addition, the patients’ varying
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circumstances will result in differences in individual outcomes that are
not attributable to care, which may lead to misinterpretation of the data.
Clinicians worry that inadequate case-mix control will bias comparisons
of quality and hurt their reputation and reimbursement.
Performance measure developers were concerned about the reliability
and validity of data collected in clinical practice. The need to collect data
according to strict protocols to ensure comparability may conflict with
the day-to-day uncertainties and fluctuations in clinical practice. There-
fore the participants need to agree on the selected performance measures
and interpret the results cautiously. The tension among the participants
on this point was most apparent in mental health care in the Nether-
lands, where an integrated PRO collection system is currently being
implemented. One expert warned: “An important message to insurance
companies is that they should be very prudent in using PRO data for
reimbursement consequences. If they jump to conclusions based on the
wrong interpretation of data, clinicians may be tempted to manipulate
data or withdraw from participation.”
Building trust between clinicians and purchasers of care was consid-
ered a key factor for success, requiring the engagement and commitment
of all parties to allay concerns and gain the cooperation of stakehold-
ers. Several experts mentioned that for public reporting, only aggregate
data at the level of the organization should be used. Data on individual
clinicians should be used confidentially only in quality improvement to
avoid unintended consequences related to misinterpretation.
Advancing PRO Measurement: Facilitators and
Barriers
Sociopolitical Context. PROmeasurement is important to policymak-
ers in the 3 countries we studied, and experts recognize it as an important
motivator for quality improvement. However, we also found significant
barriers. Although policymakers, payers, and purchasers of health
care typically want short-term results, implementing these innovative
measurement programs may take several years. Moreover, tackling the
complexity of the routine collection of sufficiently valid and reliable data
to profile provider performance will require a substantial investment.
Using PRO data to support contracting or commissioning decisions
will depend on the development of reliable and valid performance
measures and the interpretation and translation of the results. How
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to do this routinely has not yet been worked out fully. As one expert
commented: “I think what’s most important is the data are accurately
analyzed, that the data actually be reflective of the practice or the
individual practitioner or the population of patients. That’s my biggest
concern.”
Experts from the United States confirmed the complex steps in the
NQF pathway that are necessary for the successful integration of data
collection. According to an expert, “I think they [NQF] are premature in
using patient-reported outcomes as system-level performance measures.
I don’t think we know enough, and I think their scientific basis for doing
this is inadequate, and I think they’re going to get a lot of pushback
about it.”
Organizational Level. The respondents identified 3 main factors for
successfully establishing routine data collection: (1) the availability
of electronic data collection, (2) the need to avoid disrupting the
workflow, and (3) the need to obtain high response rates from patients.
Most of the experts regarded electronic data collection and the integra-
tion of data in electronic health records as an opportunity to provide
immediate feedback to clinicians and to avoid duplication of data stor-
age. But they also brought up the challenge of complexity: Having
sophisticated IT capabilities implies a complex system, which makes
it more difficult to integrate routine PRO measurement into electronic
health records. Although organizations with stand-alone PRO-recording
applications were interested in integrating the data collection into elec-
tronic health records, they also saw an advantage in their stand-alone
approach that avoided the challenge of embedding PRO collection in
the electronic health record. One expert reported: “Then we changed our
electronic medical record system, which has actually set us back a few
years because we had it exactly the way we wanted it, but we couldn’t
integrate it into the new system.”
Experts considered avoiding a disruption of workflow to be crucial to
establishing routine data collection. Experts envision patients being en-
couraged to complete questionnaires at home or in the clinic before their
visit with a physician. Several health care organizations in our sample
even made available computers or tablets in the waiting room, and some
arranged for assistance to patients in completing the questionnaires. One
expert maintained: “Workflow is one of the biggest issues. Because if
you’re going to integrate this, they have to change the way they do their
workflow. So the schedulers who are on the phone have to instruct the
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patient how to sign up for the portal and manage. There are a lot of
operational details around adjusting changing workflows.”
Experts saw an important barrier in the collection of longitudinal
data with repeated measurements: “The hard part is if you’re following
patients longitudinally over time and you want to get deltas with dif-
ferences, it’s really hard to get a high percentage of follow-up patients
at 3 months, 6 months, or a year because patients don’t want to then
fill out the survey, particularly if they’re not being attached back to an
appointment.”
Role of Clinicians. Experts agreed that the meaningful use of PRO
data in the patient-provider interaction requires clinicians’ full engage-
ment: “It is essential that the clinician discuss the outcomes with the
patient. Patients are very responsive to filling out questionnaires if they
feel that the results are actually being used for their treatment.”
Opinion leaders (“champions”) were viewed as necessary to advo-
cate for the added value of collecting patient-reported outcomes and to
lead the needed changes. Experts suggested that implementing PRO
measures in clinical practice should start with small-scale projects with
willing clinicians, rather than imposing projects on teams with limited
interest or readiness. Participants emphasized that “just getting started”
is a useful way to overcome initial resistance because clinicians can then
see directly that PRO data reveal aspects of their patients’ health that
support clinical decisions. An expert pointed out: “And so it was really
the team that set the questions and told me how they wanted to see the
data . . . they led the process, and me allowing them to lead the process
and being willing to compromise and collaborate with them was what
drove this.”
Experts confirmed that clinicians may have difficulty interpreting
PRO data, making them reluctant to discuss the results with their pa-
tients: “The most important thing is that clinicians are able to interpret
the data . . . you should teach them how to interpret the scores, about
minimal important differences, and how to use the data in diagnosis and
evaluation of treatment.”
PROMeasurement as an Innovation. When viewingPROmeasurement
as an innovation, we identified 2 main themes: the relationship between
the characteristics of PRO measures and the consequences of using the
measures for varying purposes, and the further development of PRO
performance measures. PRO measures can be described in several ways,
but a key distinction is whether they are generic or disease specific,
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because this may alter the value of PRO measures for specific purposes.
Clinicians usually prefer disease-specific measures for use in clinical
practice, and policymakers prefer generic quality-of-life measures to
enable comparability across conditions, across settings of care, and across
health care interventions. Experts generally agreed that the parallel use
of both types of measures seems feasible as long as the burden for patients
is limited. The use of PROMIS item banks with their applicability across
a wide variety of diseases and conditions was considered promising for
implementation in clinical practice, even though they currently are
being used mainly for research purposes.
Aggregation of data, effective recruitment, and high response rates
are important components of successful performance measurement. For
procedures with a short-term follow-up, such as the approach in England
for elective surgery, the response rates of patients is high, 75%.28 But
the experts acknowledged that response rates may fall during long-term
follow-ups in managing chronic disease. One expert observed: “What
we see is that it is very important that clinicians discuss the results of
the PRO measurements with their patients. Patients really appreciate
this interaction and are then very happy to comply with long-term
follow-up.”
The experts disagreed on the importance of risk adjustment. Some ad-
vocated for limited risk adjustment to avoid overadjustment and the loss
of relevant differences in providers’ outcomes. Others argued that risk ad-
justment should be as sophisticated as possible to adjust for confounders
and to address the fear of clinicians that data will be misinterpreted and
lead to providers’ cherry-picking of patients. The stratification of pa-
tients into subgroups instead of risk- or case-mix adjustment was viewed
as a way of serving both objectives.
Discussion
Our international study showed that experts from 3 key stakeholder
groups support the integrated collection of PRO data and the use of
PRO results for several different purposes. Many building blocks for
establishing an integrated approach are already in place, such as the
availability of PRO measures, data system capabilities, motivation of
stakeholders, and performance-reporting systems able to use the results.
The implementation of PRO measurement in the patient-provider
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interaction and the use of PRO performance measures at a national
or state level, however, continue to be in 2 separate worlds—the
clinical care sphere and the performance measurement and reporting
sphere—with limited communication between them.
We identified several examples of integrated approaches suggesting
that integration is feasible, but we also described the complexity of
steps necessary to establish integrated data collection. The examples
also highlighted stakeholders’ competing views of using PRO data for
both clinical practice and performance measurement. Integrating PRO
data collection has advantages. Data need to be collected only once,
thereby increasing efficiency and reducing the burden for patients and
clinicians. In addition, the feedback of aggregated data derived from the
same source used to support clinical care for individual patients makes
the results more meaningful to clinicians and promotes patient-centered
care. Such meaningful use could encourage the routine collection of data
and enhance patients’ participation.
The integrated data collection model also has some disadvantages,
chief among them being the complexity of integrating data collection
into clinical practice and the imperfectly aligned requirements for the
reliability and validity of measures useful in clinical practice and as
performance measures.7,10,15 The data collection should be rigorous but
should not interfere with clinical practice workflow. The variability of
practices’ workflow will be a challenge to obtaining truly comparable
PRO data. Because these different purposes appeal to different stake-
holders with different interests and expectations, an integrated approach
must deal not only with the reliability and validity of data, but also with
choosing appropriate analyses and presentations of data.We do not know
yet whether the desired alignment of collaborative objectives for PRO
measurement is possible. The challenge in bridging these interests is not
unique to PRO measurement but also is relevant to other types of per-
formance measures, such as those for identifying low-value services.29,30
Barriers and facilitators related to the implementation of PRO mea-
surement have been assessed in 2 published systematic reviews. One
examined routine outcome measurement in allied health professions—
including PRO measures—at the individual, managerial, and organi-
zational levels.31 The second categorized facilitators for and barriers to
practical considerations, attitudes toward the value of the data, method-
ological concerns, and the impact of feedback on patient care.32 Our
study points to the relative priority of these barriers and facilitators
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among experts currently attempting to implement PRO data collection
and also looks at the challenge of integrating the use of PRO measure-
ment for both clinical practice and performance measurement.
Implications for Policy
Our key informants identified programs in 3 countries, suggesting that
the integrated collection and use of PRO data in both clinical practice
and performance measurement are feasible. But we also learned that the
effort to create these programs is substantial. First, providers, patients,
and purchasers of care must agree on a common vision. Building trust
among stakeholders that the data will not bemisused seems fundamental
to success. Second, integrated measurement systems have not been fully
validated for evaluating the quality of care, as the science that supports
the use of PROs as performance measures is still rudimentary compared
with other areas of measurement. For example, little is known about the
effects on quality and access to care of purchasers using PRO data for
selective contracting or other incentive programs. Third, a commitment
by health care providers to the collection of reliable and valid data using
standardized protocols would be necessary to sustain such a program.
Fourth, we believe that if patients are to become advocates, they must see
this data collection as beneficial to their health and health care. Engaging
patients and the public in the integrated use of PRO measurement to
establish patient-centered care and accountability could be an important
motivator for the other stakeholders.
Is the use of PRO data in performance measurement worth these
substantial efforts? Several systematic reviews show that the feedback
of PRO data to health care professionals in clinical practice can improve
the quality of patient care, with stronger evidence for improvements in
the care process than in health outcomes.33-35 Given the small number
of programs, there are few rigorous studies of the effects of using PRO
data as a performance measurement tool. A systematic review by Boyce
and Browne34 identified only 1 study of performance feedback at the
group level, and it found no effect on performance. Another recently
published study suggested that hospital performance in England was
not altered by the introduction of routine patient-reported outcome
measures in surgery.36 The authors concluded that the manner in
which results are communicated, the need for timely feedback, and
the inclusion of suggested actions to improve PRO results might be
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necessary. Qualitative studies show that the use of PRO data as a
quality improvement tool is complex and that feedback tailored to
support the interpretation of PRO data is necessary to stimulate quality
improvement. This becomes even more important with the feedback of
aggregate data in understanding variation in outcomes among clinicians
or provider organizations.32,37 These findings echo studies of the use of
patient experience data in performance measurement.38 These studies
suggest the need to embed performance measurement in a formal
quality improvement program. In addition, the use of PROs would
benefit from greater clarity regarding the aims and purposes of each
application, together with a better understanding of the circumstances
that are likely to enhance success. The existing evidence to inform this
is currently the subject of a realist synthesis of the literature.39
The 3 nations we studied have different approaches to financing and
organizing health care. While the themes we uncovered were common
to these countries, our results suggest that policy solutions are likely
to differ among health care systems. The English approach, which is
relatively centralized, may be feasible in a system with a national health
service but not in a health care system that relies heavily on the private
sector (such as in the United States). England has enhanced the use of
PRO data in clinical practice by making patient-level data available to
providers for quality improvement purposes.40 Regional organizations
help providers41 and commissioners42 interpret and use the PRO data.
The Netherlands encourages the integrated use of PRO measures in
clinical practice and performance measurement for the long term by
aligning local initiatives of provider organizations with a national pro-
gram for data collection.22 In the United States, initiatives are aimed at
embedding PRO measurement strategies in electronic health records,
an approach that carries some risk, as it depends on the cooperation of
several relevant, but independent, private stakeholders.43
Limitations
The 3 jurisdictions we studied may not describe how PROs are collected
and used in other countries that may be actively pursuing this agenda
(eg, Canada, Sweden, and Australia). Our selection of organizations and
key informants was based on purposive sampling informed by published
research papers and reports available to us. This sampling strategy is not
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designed to produce a representative sample of experts in the field but
to provide a base for identifying determinants and exploring future di-
rections for implementation and policy. Although our sample may limit
the generalizability of our findings, our results do seem to align with the
themes identified in a recent systematic review.32 By design, our sample
did not include patients, consumers, or payers because we were inter-
ested primarily in the dynamics among provider organizations, measure
developers, and quality-reporting programs. Repeating the study with
a broader set of stakeholders could be useful.
Conclusion
We found that experts in clinical practice and performance measure-
ment supported the integrated collection of PRO data for use in both
clinical care and performance measurement. At present, though, the
measurement of PROs to support patient-provider decisions and the use
of PRO performance measures to evaluate health care providers operate
in 2 separate spheres. Several steps could advance integration, includ-
ing meaningful feedback of PRO performance data to clinicians and
connecting the data to clinical practice in order to stimulate quality
improvement activities. The use of PROs would benefit from greater
clarity regarding the aims and purposes of the various applications; a
shared vision by providers, purchasers, and patients; and the establish-
ment of trust among clinicians, provider organizations, and purchasers
of care concerning the prudent use of PRO performance measures.
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